• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 15, 2024 at 11:02: AM
via Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. When the year was over, the company’s revenue was down 41% and its shares had plunged by 44%.

article source
 






Top Bottom
Back
Quote